Chai Discovery
AI drug-discovery startup building models for molecular and antibody design
Biotech
📍 San Francisco, CA
Founded 2024
Current Valuation
$1.3B
as of 2026-Q2
UNICORN
Chai Discovery applies AI to molecular and antibody design for drug discovery. It appears on both Forbes AI 50 2026 and CB Insights AI 100 2026, making it a high-signal private AI biotech gap for the tracker.
Company Profile
Growth
Forbes reported valuation increased from ~$150M to ~$1.3B in 15 months
Fundraising Status
Growth · 2 mo ago
privateTotal raised $225M
Latest Funding Round
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Growth | — | Apr 2026 | Forbes AI 50 profile | — |
Founders & Key People
Joshua Meier
Products
- AI molecular design models
- Antibody-design models
- Drug-discovery platform
Competitors
Isomorphic Labs · Xaira Therapeutics · Insitro · Generate:Biomedicines · Recursion
AIBiotechAI Drug DiscoveryForbes AI 50CB Insights AI 100
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q2. Refreshed quarterly.